Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment

Last updated: September 15, 2025
Sponsor: Vanderbilt-Ingram Cancer Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Melanoma

Treatment

Tissue and blood collection

Clinical Study ID

NCT01205815
VICC MEL 09109
  • Ages > 18
  • All Genders

Study Summary

The purpose of this research is to identify biological characteristics occurring in the initiation and progression of melanoma.

Eligibility Criteria

Inclusion

Inclusion criteria

  • Pathologically-proven diagnosis of melanoma.

  • Patient must have a test or procedure that has the potential to provide left-over tissue that can be banked for future research purposes OR the patient has already had a diagnostic or therapeutic procedure but who has not yet been approached to participate is also eligible.

Exclusion criteria

  • Any patient with significant contraindications to venipuncture (e.g., severe anemia) will be excluded from blood collection procedures. However, if the patient provides consent and a paraffin-embedded block or 10-15 unstained slides of their tissue diagnosis, they will not be excluded from this protocol.

  • Any patient unable or unwilling to provide consent.

Study Design

Total Participants: 3000
Treatment Group(s): 1
Primary Treatment: Tissue and blood collection
Phase:
Study Start date:
June 03, 2010
Estimated Completion Date:
June 30, 2027

Connect with a study center

  • Vanderbitl-Ingram Cancer Center

    Nashville, Tennessee
    United States

    Site Not Available

  • Vanderbitl-Ingram Cancer Center

    Nashville 4644585, Tennessee 4662168
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.